

University of Wisconsin-Madison Institutional Biosafety Committee

Minutes of Regular Meeting Open Session

Date: 9/2/2026

Present: Matt Reynolds, Dennis Halterman, Donna Neumann, Yevgenya Grinblat, Andrea Ladd, Amita Kapoor, Andy Attwood, Ryan Stoffel, Garret Suen, Joel Malak, Clint Morgan, Ryan Behrens, Barak Blum, Sabine Pellett, Steve Garvis

Consultants: Tony McGrath, Lissa Koop, Christina Pier, Heather Mc Fadden, Carrie Ensrud, Jennifer Wang, Quin Koehl

OBS: Tony McGrath, TJ Whyte, Karen Demick, Christina Pier, Andrea Ladd, Stephanie Kutz, Tara Schnell, Megan Dixon, Erin Plisch, Donald Busalacchi, Carrie Ensrud, Matthew Dutcher, Kathy Krasny, Quin Koehl

Guests: Tu Anh Huynh, Huynh Lab Sarah Johnson, CALS Lyndon Tuffuo, VA Hospital

Call to order: The meeting was called to order by Garret Suen, at Zoom at 1:30 pm

Announcements: The IBC meeting is open to the public.

Review of Minutes: A motion to approve the open session minutes of the following IBC meetings was Unanimously adopted.

Institutional Biosafety Committee meeting on (8/5/2026)

Institutional Biosafety Committee meeting on (8/19/2026)

08/05/2026 Abstain: Andrea Ladd 08/19/2026 Abstain: Sabine Pellett

Approval of Registered Protocols: A motion to approve registered protocols was Unanimously adopted

Other business - open session

- **Agenda Items - Documents For Open Session:**
- **List of Registered Protocols_070126-080526_AM.xlsx**
- **List of Registered Protocols_070126-080526_GP.xlsx**

Review of research protocols - open session

- **B00001275**
- **B00001285**
- **B00001287**
- **B00001288**

Review of research amendments - open session

- **B00000089-AM027**
- **B00000173-AM019**
- **B00000243-AM007**
- **B00000272-AM024**
- **B00000454-AM023**
- **B00000720-AM009**
- **B00000749-AM017**
- **B00000887-AM007**
- **B00000891-AM002**
- **B00000894-AM007**
- **B00000969-AM007**
- **B00000972-AM011**
- **B00001256-AM001**

Announcements null

The meeting adjourned 3:47 pm

- **Bio Protocol Number: B00001275**

PI Name: [REDACTED]

Protocol Title: Energy Metabolism in Retinal Pigment Epithelium Health and Disease

Motion: IBC approved with contingencies

Motion Made By: Andrea Ladd

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Abstain: Donna Neumann

Biosafety Level: BSL2; ABSL1, BSL2; BSL1; ABSL1, BSL2; ABSL1; BSL1; ABSL1; ABSL1;
ABSL1; ABSL1; ABSL1;

Containment Equipment: Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Chemical fume hood; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8);

Summary of IBC Review: This is a new protocol from a group that studies the high metabolism of retina tissue and consequences of disruption of this activity in retinal degeneration and blindness. The IBC discussed PPE use, disinfection procedures, and some administrative updates.

- **Bio Protocol Number: B00001285**

PI Name: [REDACTED]

Protocol Title: Human cell culture, human biospecimens and murine models for study of the immune system

Motion: IBC approved protocol

Motion Made By: Amita Kapoor

Motion Seconded By: Barak Blum

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL2; BSL2; BSL2; ABSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; BSL1; BSL2; BSL1; ABSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC),

Chemical fume hood, Other - bioBubble; Chemical fume hood; Other - This is a vivarium procedure room and will be used for irradiation of mice only ; Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-4-b); (III-F-8);

Summary of IBC Review: This is a new protocol proposing studies with autoimmune disease and site-specific immunity in mucosal and exocrine tissues focusing on graft-versus-host disease in non-self blood cell transplant recipients. The IBC discussed procedures for PPE while using a microscope.

- **Bio Protocol Number: B00001287**

PI Name: [REDACTED]

Protocol Title: Investigating cellular mechanisms of cell cycle exit and fate change

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Steve Garvis

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL1; BSL2; BSL2; ABSL1, BSL2; ABSL1;

Containment Equipment: Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to

pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-2-a); (III-E-3); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-1); (III-F-4) (III-F-5);

Summary of IBC Review: This is a new protocol from a lab whose work combines advanced imaging with large-scale protein analyses to track how signaling changes unfold dynamically. The IBC discussed the need for additional detail for work outside containment.

- **Bio Protocol Number: B00001288**

PI Name: Jasmine Childress

Protocol Title: Childress Lab Biosafety Protocol

Motion: IBC approved with contingencies

Motion Made By: Yevgenya Grinblat

Motion Seconded By: Dennis Halterman

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum

Biosafety Level: Not applicable (non-laboratory area); BSL2; BSL2;

Containment Equipment: Not applicable; Biological safety cabinet (BSC); Other - Downdraft necropsy table;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: null

Summary of IBC Review: This is a new protocol proposing the study of parasite ecology by identifying parasitic worms in wild animal scat and carcass samples. The IBC discussed work outside containment, disinfection and disposal methods, laboratory facility airflow, and risks for work with avian specimens of unknown health status.

- **Bio Protocol Number: B00000089-AM027**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 027 for The molecular pathogenesis of emerging infectious diseases | BSL-2

Motion: IBC approved with contingencies (protocol must go back to IBC reviewers)

Motion Made By: Ryan Behrens

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum

Biosafety Level: ABSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL1; BSL1; BSL2; ABSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions

are required for approval.

NIH Guidelines Requirements: Proposed work requires NIH approval under the NIH Guidelines. A Minor Action will be submitted. Final approval will be withheld until NIH approval is granted.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-2-a); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-7); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E-1); (III-E-1); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies emerging pathogens and aims to develop novel vaccines for flaviviruses, enteroviruses, influenza viruses, and other viruses. This amendment proposes to add the a vaccine and a replication-incompetent recombinant chikungunya (CHIKV) pseudovirus system to existing vaccination project. The IBC discussed emergency response procedures, verification of replication-defective strain, and biosafety level designation of CHIKV. The IBC supports work with attenuated CHIKV at BSL2; a Minor Action request will be submitted for NIH-OSP approval of the downgrade.

- **Bio Protocol Number: B00000173-AM019**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 019 for Genetics of infectious diseases

Motion: IBC approved protocol

Motion Made By: Andrea Ladd

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent Barak Blum

Biosafety Level: BSL1; BSL2; BSL3; BSL1; BSL2; BSL2; BSL1;

Containment Equipment: Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional

controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-E); (III-E); (III-F-8);

Summary of IBC Review: This lab studies the evolution of *Mycobacterium tuberculosis*. This is an amendment proposing to add an attenuated *M. tuberculosis* strain. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000243-AM007**

PI Name: Michael Sussman

Protocol Title: Amendment/Renewal 007 for Molecular Biology of *Arabidopsis thaliana*, *Medicago truncatula*, *Electrophorus electricus* and Brine Shrimp (*Artemia*)

Motion: IBC approved protocol

Motion Made By: Andrea Ladd

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL1; BSL1; BSL1; BSL1; BSL1; BSL1; BSL1; BSL1;

Containment Equipment: Other - Laminar flow hoods (2); Not applicable; Not applicable;

Not applicable; Chemical fume hood; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-E-2-a); (III-E); (III-E); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies the molecular biology of plant and animal growth and development. This amendment proposes the addition of transgenic hemp and soybean plants. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000272-AM024**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 024 for Designing protein-based small molecule sensors and engineering phage

Motion: IBC approved with contingencies

Motion Made By: Sabine Pellett

Motion Seconded By: Steve Garvis

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum

Biosafety Level: ABSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; ABSL2; ABSL2; BSL2; Not applicable (non-laboratory area); BSL2; BSL2; ABSL2; BSL2; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC), Other - Ventilated enclosure (i.e. bioBubble enclosure); Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable - SAIRF location for animal imaging; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Chemical fume hood; Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Chemical fume hood; Chemical fume hood; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-B-1); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a)(III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E); (III-E-1); (III-F-8); (III-F-8); (III-F-1); (III-F-4) (III-F-5);

Summary of IBC Review: This lab investigates designer proteins as sensors to engineer

bacteria for chemicals production. This amendment proposes to add anatoxin-a toxin. The IBC discussed disinfection and PPE procedures, spill protocols, and additional detail for materials used in containment.

- **Bio Protocol Number: B00000454-AM023**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 023 for The role of nutrient-sensing kinases signaling in diabetes, metabolism and aging

Motion: IBC approved with contingencies

Motion Made By: Donna Neumann

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL1; BSL1; BSL1; ABSL1; BSL2; BSL2; BSL1; BSL1; ABSL2; BSL1; BSL2; BSL2; BSL1; ABSL2; ABSL1; ABSL1; BSL2; ABSL1;

Containment Equipment: Not applicable; Not applicable; Biological safety cabinet (BSC);

Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable;

Biological safety cabinet (BSC); Chemical fume hood; Not applicable; Not applicable;

Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Not

applicable; Not applicable; Biological safety cabinet (BSC); Chemical fume hood; Biological

safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Not

applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E); (III-E-1); (III-E-1); (III-F-8); (III-F-8); (III-F-8);

(III-F-8); (III-F-1);

Summary of IBC Review: This lab studies pathways involved in metabolism regulation and metabolic diseases. The amendment proposes to add new constructs, a new project, and updates to disinfection/inactivation procedures. The IBC discussed the proposed changes and had no additional concerns once the contingencies regarding disinfection and inactivation procedures, spill protocol, and detail updates for viral vector work are addressed.

- **Bio Protocol Number: B00000720-AM009**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 009 for Mechanistic investigation of signaling mechanisms that mediate bacterial growth, stress responses, and virulence

Motion: IBC approved with contingencies

Motion Made By: Sabine Pellett

Motion Seconded By: Dennis Halterman

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum

Biosafety Level: ABSL2; ABSL2; ABSL2; ABSL2; ABSL2; ABSL2; ABSL2; Not applicable (non-laboratory area); BSL2; BSL1; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC); Ventilated HEPA-filtered housing or rack system; Ventilated HEPA-filtered housing or rack system; Ventilated HEPA-filtered housing or rack system; Biological safety cabinet (BSC); Ventilated HEPA-filtered housing or rack system; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-E); (III-E-1); (III-E); (III-E-1); (III-F-8); (III-F-8);

Summary of IBC Review: This lab studies bacterial pathogenesis mechanisms towards development of antibacterial treatments for human diseases and food production. This amendment proposes to add anaerobic chamber, several gut commensal bacteria, and mouse colonization studies. The IBC discussed specimen transport containment, disinfection procedures, spill protocols and some administrative changes.

- **Bio Protocol Number: B00000749-AM017**

PI Name: Jason Peters

Protocol Title: Amendment/Renewal 017 for Antibiotic-genetic studies of pathogenic bacteria

Motion: IBC approved protocol

Motion Made By: Amita Kapoor

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum, Donna Neumann

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL1; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Other - We have purchased a second BSC that will reside in room 6228. We will perform all aerosol generating manipulations in the two BSCs. We will only work with BSL2 organisms in 6230 in closed containers.; Not applicable - We will use the luminometer and plate reader with closed plates.; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-E); (III-E); (III-F-8); (III-F-1); (III-F-8); (III-F-4) (III-F-5);

Summary of IBC Review: This lab identifies genes that can be exploited to make pathogenic bacteria more susceptible to antibiotics. This amendment proposes to introduce antibiotic resistance that can be naturally acquired into this pathogen. The biosafety is adequately addressed.

- **Bio Protocol Number: B00000887-AM007**

PI Name: Dennis Halterman

Protocol Title: Amendment/Renewal 007 for Molecular and genetic studies of potato disease resistance

Motion: IBC approved protocol

Motion Made By: Andrea Ladd

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL1, BSL1-P; BSL1; BSL1; BSL1-P; BSL1; BSL1; BSL1-P;

Containment Equipment: Other - Plant growth chamber; Other - locked incubator; Biological safety cabinet (BSC), Chemical fume hood, Ventilated HEPA-filtered housing or rack system; Not applicable; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-E-2-a); (III-E); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This lab studies diseases of potato plants and interactions between microbes within the potato host. The amendment proposes to add work with plant pathogen *Alternaria solani* (early blight), which will be modified to express genes from Potato Virus Y.

The expected outcome is attenuation of pathogenicity in *A. solani*. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000891-AM002**

PI Name: Elizabeth Wright

Protocol Title: Amendment/Renewal 002 for Cryo-Electron Microscopy Research Center at UW-Madison

Motion: IBC approved with contingencies

Motion Made By: Amita Kapoor

Motion Seconded By: Yevgenya Grinblat

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Abstain: Steve Garvis, Ryan Behrens Absent: Barak Blum, Donna Neumann

Biosafety Level: Not applicable (non-laboratory area); BSL2; BSL2; Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); BSL2; BSL2; BSL2; Not applicable (non-laboratory area); BSL2; Not applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2; Not applicable (non-laboratory area); BSL2; BSL2; BSL2;

Containment Equipment: Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Other - Only small quantities of sample will enter this space, remaining unfixed sample will be moved back to B1106G; Not applicable; Other - Other - Only small quantities of sample will enter this space, remaining unfixed sample will be moved back to B1106G; Not applicable; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: null

Summary of IBC Review: The Cryo-Electron Microscopy Research Center (CEMRC) is a core lab resource for high-resolution electron microscopy-based imaging of biological, biochemical, or soft materials samples. This amendment proposes to add updates to locations, emergency response procedures and disinfection practices. The IBC discussed the proposed changes and had no additional concerns once the contingencies regarding spill and release procedures, disinfection protocol and some administrative updates are addressed.

- **Bio Protocol Number: B00000894-AM007**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 007 for The Hematopoietic Stem Cell Microenvironment

Motion: IBC approved with contingencies

Motion Made By: Yevgenya Grinblat

Motion Seconded By: Dennis Halterman

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum, Donna Neumann

Biosafety Level: BSL2; BSL2; BSL1; BSL1; BSL2; BSL1; BSL1; BSL1; BSL1; Not applicable (non-laboratory area); BSL2; BSL1; Not applicable (non-laboratory area); BSL1; BSL2; BSL1; BSL1, BSL2, Other - BSL1 when working with zebrafish and mouse cells, BSL2 signage when working with human cells;

Containment Equipment: Other - BioBubble; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-D-4) (III-D-4-a) (III-D-4-b); (III-D-2-a); (III-D-1-a) (III-D-1-b); (III-E-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This lab studies blood stem cell development for the treatment of blood diseases and cancers. This amendment proposes to remove work with viruses and some administrative changes. The IBC discussed the proposed changes and had no additional concerns once the contingencies regarding PPE use, containment, spill protocol, and emergency response are addressed.

- **Bio Protocol Number: B00000969-AM007**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 007 for The Development of Antibodies Targeting Cancer-Associated Proteins

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum, Donna Neumann

Biosafety Level: BSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; BSL2; ABSL2; BSL2; BSL2; ABSL2; ABSL2;

Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Other - Water filtration devices for shark tank; Not applicable; Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and/or laboratory staff must complete required institutional biosafety training. Final approval will be withheld until required biosafety training is complete.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions

are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-E); (III-E-1); (III-F-8);

Summary of IBC Review: This lab studies the use of recombinant methods to develop antibodies against targets associated with highly aggressive metastatic forms of cancer. This amendment proposes the addition of a lentiviral vector, cell lines, and flow cytometry. The IBC discussed the proposed changes and had no additional concerns once the contingencies regarding microbe details, containment, PPE use, disinfection methods, spill and release procedures, as well as administrative updates are addressed.

- **Bio Protocol Number: B00000972-AM011**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 011 for Investigating Sjogren's syndrome and autoimmunity

Motion: IBC approved with contingencies

Motion Made By: Andrea Ladd

Motion Seconded By: Amita Kapoor

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Abstain: Matt Reynolds Absent: Barak Blum, Donna Neumann

Biosafety Level: BSL2; ABSL2; BSL2; Not applicable (non-laboratory area); BSL2; BSL2; BSL2; BSL2; ABSL1; BSL1; ABSL2; Other - fume hood; BSL2; BSL2; BSL2; BSL2; Not applicable (non-laboratory area); BSL1; BSL2; BSL1; BSL2;

Containment Equipment: Chemical fume hood; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Not applicable; Not applicable; Chemical fume hood; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC); Not applicable; Not applicable; Chemical fume hood; Not applicable; Biological safety cabinet (BSC);

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the

conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-F-8); (III-F-8); (III-F-1);

Summary of IBC Review: This protocol was previously approved under another PI. The laboratory studies Sjogren's Syndrome, autoimmunity, and mesenchymal stromal cells. This amendment proposes a PI change until the laboratory closes in a few months. No changes in research are proposed, except to remove studies that are no longer performed. The IBC discussed the proposed changes and had no additional concerns.

- **Bio Protocol Number: B00001256-AM001**

PI Name: Michal Engelman

Protocol Title: Amendment/Renewal 001 for Wisconsin Longitudinal Study ILIAD Whole Blood Collection by Field Interviewer Phlebotomist

Motion: IBC approved protocol

Motion Made By: Steve Garvis

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by voice vote

Nay Votes, Abstentions, Absentees: Absent: Barak Blum, Donna Neumann

Biosafety Level: Not applicable (non-laboratory area); Not applicable (non-laboratory area) - Pre-scouted locations will meet or exceed criteria outlined below.;

Containment Equipment: Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work is not subject to the NIH Guidelines.

Administrative: null

NIH Guidelines:

Summary of IBC Review: This lab's work includes collecting blood samples from participants to examine factors that impact dementia and late life cognitive function. This amendment proposes to switch from a manual disposable transfer pipettes for the blood products to an autopipettor for the whole blood and plasma. Biosafety is adequately addressed.

Andrea Ladd reminded meeting attendees, any messages sent to her or Stephanie during the IBC Meeting should be sent in the meeting Zoom chat, which will be monitored during the meeting. Messages sent by other means may be missed during the meeting time.

University of Wisconsin-Madison Institutional Biosafety Committee

Minutes of Regular Meeting Closed Session

Date: 9/2/2026

Present: Matt Reynolds, Dennis Halterman, Donna Neumann, Yevgenya Grinblat, Andrea Ladd, Amita Kapoor, Andy Attwood, Ryan Stoffel, Garret Suen, Joel Malak, Clint Morgan, Ryan Behrens, Barak Blum, Sabine Pellett, Steve Garvis

Consultants: Tony McGrath, Lissa Koop, Christina Pier, Heather Mc Fadden, Carrie Ensrud, Jennifer Wang, Quin Koehl

OBS: Tony McGrath, TJ Whyte, Karen Demick, Christina Pier, Andrea Ladd, Stephanie Kutz, Tara Schnell, Megan Dixon, Erin Plisch, Donald Busalacchi, Carrie Ensrud, Matthew Dutcher, Kathy Krasny, Quin Koehl

Guests:

Call to order: The meeting was called to order by Garret Suen, at Zoom at 1:30 pm

Announcements: The IBC meeting is closed to the public.

Review of Minutes: A motion to approve the closed session minutes of the following IBC meetings was Unanimously adopted.

Institutional Biosafety Committee meeting on (8/5/2026)

Institutional Biosafety Committee meeting on (8/19/2026)

08/05/2026 Abstain: Andrea Ladd

Other business - closed session

- **Agenda Items - Documents For Closed Session:**

Review of research protocols - closed session

- **B00001238**
- **B00001280**
- **B00001284**
- **B00001286**

Review of research amendments - closed session

- **B00000263-AM043**
- **B00000934-AM015**

Announcementsnull

The meeting adjourned 3:47 pm

- **Bio Protocol Number: B00001238**

PI Name: [REDACTED]

Protocol Title: In Vitro and In Vivo Studies of Retinal Neurons

Motion: IBC approved with contingencies

Motion Made By: Donna Neumann

Motion Seconded By: Sabine Pellett

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: ABSL1, ABSL2; BSL2; ABSL2; ABSL2; ABSL2; ABSL1; ABSL1; BSL2; ABSL2; BSL2; ABSL2; BSL2; ABSL2; BSL2; ABSL2;

Containment Equipment: Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Other - Autoclave; Biological safety cabinet (BSC), Ventilated HEPA-filtered housing or rack system; Ventilated HEPA-filtered housing or rack system - Animal Transfer Station; Chemical fume hood, Ventilated HEPA-filtered housing or rack system; Not applicable; Other - Downdraft table; Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC); Not applicable; Chemical fume hood; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing

information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-1-a) (III-D-1-b); (III-D-3-a) (III-D-3-b) (III-D-3-e); (III-E-1); (III-E-1); (III-F-8); (III-F-1);

Summary of IBC Review: This is a new protocol proposing to study eye-brain communication and to develop stem cell-based therapies for blinding diseases. The IBC discussed containment for work with inhalation hazards, work in shared laboratory spaces, disinfection, PPE practices, and some administrative edits.

- **Bio Protocol Number: B00001280**

PI Name: Kyle Richards

Protocol Title: [REDACTED] for BCG-Unresponsive/Chemotherapy-Unresponsive HR-NMIBC

Motion: IBC approved with contingencies

Motion Made By: Donna Neumann

Motion Seconded By: Joel Malak

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC); Biological safety cabinet (BSC); Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC), Chemical fume hood;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-C-1);

Summary of IBC Review: This is a new protocol proposing a clinical trial to treat non-muscle invasive bladder cancer using a modified oncolytic herpesvirus. The IBC discussed disinfection protocols and additional administrative edits.

- **Bio Protocol Number: B00001284**

PI Name: Jon Odorico

Protocol Title: [REDACTED]

Motion: IBC approved with contingencies

Motion Made By: Joel Malak

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); BSL2; Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area); Not applicable (non-laboratory area);

Containment Equipment: Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Biological safety cabinet (BSC), Other - Closed centrifuge; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-C-1);

Summary of IBC Review: This is a new protocol proposing to evaluate the safety and efficacy of a gene-edited cell therapy in patients with Type 1 diabetes and severe hypoglycemia. The IBC discussed PPE for aerosol generating activities with human derived materials.

- **Bio Protocol Number: B00001286**

PI Name: Priyanka Pophali

Protocol Title: UW26095: Ph2 R open-label study evaluating [REDACTED]
in LBCL pts with MRD after 1st line tx

Motion: IBC approved protocol

Motion Made By: Joel Malak

Motion Seconded By: Barak Blum

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL1; Other - clinical space; BSL2; BSL2;

Containment Equipment: Biological safety cabinet (BSC), Chemical fume hood - BSC is SterilGARD Baker Company; Fume hood is technically in Immunology, but that is also B4/220- the processing area does have access to it if needed; Not applicable; Biological safety cabinet (BSC), Chemical fume hood; Biological safety cabinet (BSC) - 2 Biological safety cabinet (BSC) that are certified bi-annually.;

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and/or laboratory staff must complete required institutional biosafety training. Final approval will be withheld until required biosafety training is complete.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-C-1);

Summary of IBC Review: This is a new protocol for a clinical trial evaluating a new modified cell therapy to treat patients with B-cell hematologic malignancies. Biosafety is adequately addressed.

- **Bio Protocol Number: B00000263-AM043**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 043 for The Study of Filoviruses and other Neglected and Novel Viruses

Motion: IBC approved with contingencies

Motion Made By: Matt Reynolds

Motion Seconded By: Ryan Behrens

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; ABSL2; ABSL2; BSL3+, ABSL3+; BSL3+, BSL3-Ag; ABSL3-Ag; ABSL3-Ag; ABSL1, ABSL2; BSL2; BSL2; Not applicable; BSL2

Containment Equipment: Biological safety cabinet (BSC) and Chemical fume hood, Autoclave; Not applicable; Biological safety cabinet (BSC), Autoclave; Not applicable; Biological safety cabinet (BSC), HEPA rack system; Not applicable; Biological safety cabinet (BSC); Biological safety cabinet (BSC), HEPA rack system; Biological safety cabinet (BSC); Not applicable; Not applicable; Biological safety cabinet (BSC) Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls deviate from the standards set by the IBC for the proposed materials and activities. Revisions are required for approval.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: null

NIH Guidelines: (III-D-1-a)(III-D-1-b); (III-D-2-a); (III-D-2-a); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-4-a)(III-D-4-b); (III-D-4-b); (III-E); (III-E-1); (III-E-1); (III-E-3); (III-F-1); (III-F-8); (III-F-8); (III-F-8); (III-F-8); (III-F-8);

Summary of IBC Review: Research in this laboratory focuses on select agent and non-select agent filoviruses and coronaviruses, as well as other RG2 and RG3 viruses involved in emerging diseases. The select agent work has been approved by the Federal Select Agent Program. The IBC discussed the proposed changes and had no additional concerns once the contingencies regarding disinfection methods and administrative updates are addressed.

- **Bio Protocol Number: B00000934-AM015**

PI Name: [REDACTED]

Protocol Title: Amendment/Renewal 015 for Regulation and Analysis of Toxins

Motion: IBC approved with contingencies

Motion Made By: Ryan Behrens

Motion Seconded By: Garret Suen

Committee Action: Adopted unanimously by hand vote

Nay Votes, Abstentions, Absentees:

Biosafety Level: BSL2; BSL2; BSL2; BSL2; BSL2; BSL3; BSL2; ABSL2

Containment Equipment: BSC and chemical fume hood; Not applicable; Biological safety cabinet (BSC); Chemical fume hood; Not applicable; Biological safety cabinet (BSC); Not applicable; Biological safety cabinet (BSC)

Committee Review: The IBC has reviewed the locations, activities, and agents involved in the proposed work. The IBC considered agent characteristics including but not limited to pathogenicity, stability, and source and nature of recombinant and synthetic nucleic acids and their expressed products, as applicable.

Facilities: Facilities meet standards set by the IBC or additional controls are used effectively to mitigate risk caused by deviation from the standards.

Required Institutional Training: The PI and laboratory staff have completed required institutional biosafety training.

Lab-specific Training and Expertise: The training and expertise of personnel involved in the conduct of research meets standards set by the IBC.

PPE, Controls, and Practices: The PPE, engineering controls, and administrative controls meet the standards set by the IBC for the proposed materials and activities or additional controls are used effectively to mitigate risk caused by deviation from the standards.

NIH Guidelines Requirements: Proposed work meets the requirements set forth in the NIH Guidelines.

Administrative: Administrative revisions are required for approval (e.g., reorganizing information, removing extraneous text, correcting typos, spelling out acronyms).

NIH Guidelines: (III-B-1); (III-D-1-a)(III-D-1-b); (III-D-2-a); (III-D-4)(III-D-4-a)(III-D-1-a)(III-D-1-b)(III-D-4-b); (III-D-6); (III-E); (III-E-1); (III-E-1); (III-F-1); (III-F-8); (III-F-8)

Summary of IBC Review: Research in this laboratory focuses on select agent and non-select agent clostridial neurotoxins. The select agent work has been approved by the Federal Select Agent Program.

Summary of IBC Review: Research in this laboratory focuses on select agent and non-select agent clostridial neurotoxins. The select agent work has been approved by the Federal Select Agent Program. The IBC discussed the proposed changes and had no additional concerns once the contingencies regarding administrative updates are addressed.

Andrea Ladd gave the incident report.

No DURC report was given.

Andrea Ladd gave WVDL update – they have requested the protocol go back to study team for revisions.

Andrea Ladd provided a summary of the Draft NIH Biosafety Policy which is currently available for public comment through 10/19/2026.